Bioventus Inc
NASDAQ:BVS
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3.94
13.71
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Bioventus Inc
Operating Income
Bioventus Inc
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Bioventus Inc
NASDAQ:BVS
|
Operating Income
$1.3m
|
CAGR 3-Years
-64%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
N/A
|
|
|
Haemonetics Corp
NYSE:HAE
|
Operating Income
$215m
|
CAGR 3-Years
53%
|
CAGR 5-Years
7%
|
CAGR 10-Years
9%
|
|
|
ICU Medical Inc
NASDAQ:ICUI
|
Operating Income
$53.9m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
2%
|
|
|
Align Technology Inc
NASDAQ:ALGN
|
Operating Income
$679.5m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
7%
|
CAGR 10-Years
13%
|
|
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
Operating Income
$474.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
53%
|
CAGR 10-Years
34%
|
|
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
Operating Income
$152.7m
|
CAGR 3-Years
31%
|
CAGR 5-Years
34%
|
CAGR 10-Years
15%
|
|
Bioventus Inc
Glance View
Bioventus, Inc. global medical technology company which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. The company is headquartered in Durham, North Carolina and currently employs 1,200 full-time employees. The company went IPO on 2021-02-11. The firm is focused on developing and commercializing clinically and minimally invasive treatments that engage and enhance the body’s natural healing process. The Company’s portfolio of products includes OA joint pain treatment and joint preservation, bone graft substitutes and minimally invasive fracture treatment. The OA joint pain treatment and joint preservation is focused on orthopedics. Its bone graft substitutes (BGSs) offers portfolio of products including human tissue allografts and synthetics. Its BGS products can be used in conjunction with any orthopedic fixation and spinal fusion implant. They are designed to improve bone fusion rates following spinal fusion and other orthopedic surgeries and reduce the need for using the patient’s own bone.
See Also
What is Bioventus Inc's Operating Income?
Operating Income
1.3m
USD
Based on the financial report for Dec 31, 2023, Bioventus Inc's Operating Income amounts to 1.3m USD.
What is Bioventus Inc's Operating Income growth rate?
Operating Income CAGR 5Y
-46%
The average annual Operating Income growth rates for Bioventus Inc have been -64% over the past three years , -46% over the past five years .
You don't have any saved screeners yet
